ARCT
Arcturus Therapeutics Holdings Inc.NASDAQHealthcare$8.03+2.29%ClosedMarket Cap: $228.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.05
P/S
3.15
EV/EBITDA
-0.39
DCF Value
$-5.52
FCF Yield
-32.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.6%
Operating Margin
-101.1%
Net Margin
-88.7%
ROE
-29.1%
ROA
-24.3%
ROIC
-31.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.1M | 77.9% | $-30.0M | $-29.1M | $-1.05 | — |
| FY 2025 | $67.2M | 95.5% | $-75.0M | $-65.8M | $-2.40 | — |
| Q3 2025 | $17.2M | 80.5% | $-16.5M | $-13.4M | $-0.49 | — |
| Q2 2025 | $24.5M | 100.0% | $-11.6M | $-9.2M | $-0.34 | — |
| Q1 2025 | $29.4M | 100.0% | $-16.8M | $-14.1M | $-0.52 | — |
| Q4 2024 | $21.0M | 100.0% | $-33.4M | $-30.0M | $-1.11 | — |
| FY 2024 | $138.4M | 100.0% | $-95.7M | $-80.9M | $-3.00 | — |
| Q3 2024 | $38.8M | 100.0% | $-10.7M | $-6.9M | $-0.26 | — |
| Q2 2024 | $46.0M | 100.0% | $-21.1M | $-17.2M | $-0.64 | — |
| Q1 2024 | $32.6M | 100.0% | $-30.4M | $-26.8M | $-1.00 | — |
| Q4 2023 | $25.1M | 100.0% | $-18.3M | $-11.7M | $-0.32 | — |
| FY 2023 | $157.7M | 100.0% | $-78.2M | $-29.7M | $-1.12 | — |